DRIO DarioHealth Corp.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1533998 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-13.9%
TTM net income YoY19.5%
TTM EPS YoY-67.7%
Revenue 3-yr CAGR-3.3%
Net income 3-yr CAGR—
Margins
Gross margin57.9%
Operating margin-142.7%
Net margin-159.9%
FCF margin-111.0%
EBITDA margin-141.7%
Returns
ROE-46.6%
ROA-29.6%
ROIC (approx.)-32.4%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets36.6%
Debt / equity0.44x
Current ratio4.20x
Interest coverage-6.81x
Cash quality & payout
Operating cash flow / net income0.69x
Accruals ratio-9.1%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $5.31M | $5.18M | $5.58M | $5.23M | $5.01M | $5.37M | $6.75M | $7.60M |
| Cost of revenue | $2.17M | $1.99M | $2.38M | $2.43M | $1.99M | $2.40M | $2.87M | $3.40M |
| Gross profit | $3.15M | $3.19M | $3.20M | $2.80M | $3.02M | $2.96M | $3.88M | $4.20M |
| R&D expense | $2.29M | $2.10M | $2.38M | $2.63M | $3.33M | $3.72M | $4.11M | $5.28M |
| SG&A expense | $4.08M | $2.60M | $3.23M | $4.10M | $4.57M | $3.21M | $3.31M | $5.01M |
| Operating income | -$8.04M | -$6.48M | -$7.31M | -$8.56M | -$9.48M | -$9.20M | -$9.41M | -$11.67M |
| Interest expense | $1.09M | $1.12M | $1.15M | $1.10M | $1.16M | — | — | — |
| Pretax income | -$8.87M | -$7.60M | -$8.19M | -$8.95M | -$10.47M | -$12.99M | -$9.21M | -$9.48M |
| Income tax | -$18,000 | $328,000 | $57,000 | $83,000 | $0 | $0 | $22,000 | $155,000 |
| Net income | -$8.85M | -$7.92M | -$8.25M | -$9.03M | -$10.47M | -$12.99M | -$9.23M | -$9.63M |
| EBITDA | -$8.00M | -$6.43M | -$7.25M | -$8.50M | -$9.41M | -$9.12M | -$9.31M | -$11.11M |
| EPS (basic) | 0.73 | 0.85 | 1.25 | — | 2.96 | 3.54 | 2.87 | — |
| EPS (diluted) | 0.73 | 0.85 | 1.25 | — | 2.96 | 3.54 | 2.87 | — |
| Weighted avg. shares (diluted) | 12.06M | 9.34M | 6.58M | — | 3.14M | 2.48M | 2.37M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $27.84M | $6.63M | $14.98M | $21.80M | $31.91M | $21.95M | $27.85M | $27.76M |
| Short-term investments | $3.31M | $7.33M | $5.04M | $4.21M | — | — | — | — |
| Inventory | $3.54M | $3.72M | $4.17M | $4.32M | $4.87M | $4.61M | $4.62M | $4.75M |
| Current assets | $38.49M | $22.13M | $28.73M | $35.07M | $42.19M | $32.17M | $38.56M | $40.53M |
| PP&E, net | $479,000 | $503,000 | $511,000 | $549,000 | $578,000 | $610,000 | $646,000 | $709,000 |
| Goodwill | $57.43M | $57.43M | $57.43M | $57.43M | $57.43M | $57.43M | $57.43M | $57.43M |
| Intangibles | $14.53M | $15.00M | $15.47M | $15.93M | $16.41M | $16.88M | $17.60M | $18.76M |
| Total assets | $112.43M | $96.59M | $103.28M | $110.08M | $117.73M | $108.33M | $115.60M | $118.88M |
| Current liabilities | $9.17M | $9.58M | $9.36M | $9.32M | $9.28M | $9.75M | $19.16M | $16.64M |
| Short-term debt | — | — | — | — | — | — | $10.29M | $5.45M |
| Long-term debt | $31.25M | $31.06M | $30.93M | $30.75M | $30.62M | $30.50M | $18.90M | $23.47M |
| Total debt | $31.25M | $31.06M | $30.93M | $30.75M | $30.62M | $30.50M | $29.19M | $28.92M |
| Total liabilities | $41.16M | $41.50M | $40.90M | $42.15M | $42.79M | $44.34M | $41.90M | $46.87M |
| Shareholders' equity | $71.27M | $55.09M | $62.38M | $67.92M | $74.93M | $63.99M | $73.70M | $72.02M |
| Net debt | $3.40M | $24.43M | $15.95M | $8.94M | -$1.29M | $8.54M | $1.34M | $1.16M |
| Shares outstanding | 11.20M | 7.34M | 7.30M | 6.91M | 6.77M | 45.47M | 42.71M | 1.92M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.54M | -$6.08M | -$6.03M | -$5.89M | -$7.35M | -$6.03M | -$6.67M | -$6.73M |
| Capital expenditure | $27,000 | $38,000 | $31,000 | $26,000 | $41,000 | $44,000 | $31,000 | $21,000 |
| Free cash flow | -$5.57M | -$6.12M | -$6.06M | -$5.91M | -$7.39M | -$6.08M | -$6.70M | -$6.75M |
| Investing cash flow | $3.97M | -$2.29M | -$826,000 | -$4.23M | -$41,000 | -$44,000 | -$31,000 | -$21,000 |
| Financing cash flow | — | — | — | -$19,000 | $17.39M | $124,000 | $6.82M | $18.32M |
| Depreciation & amortization | $50,000 | $47,000 | $61,000 | $60,000 | $73,000 | $80,000 | $94,000 | $554,000 |
| Stock-based compensation | $2.21M | $632,000 | $1.44M | $2.04M | $2.95M | $2.04M | $2.34M | -$13.16M |
Free plan shows the latest 8 periods; Pro shows all 59 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.